SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System
Instrument ushers in a new phase of biologic
characterization, empowering scientists to analyze more samples and
molecules to meet next-gen drug development challenges
SCIEX, a global leader in life science analytical technologies
and Danaher operating company, presents the latest capillary
electrophoresis solution, the BioPhase 8800 system. This is the
only multi-capillary system for CE-SDS that processes eight samples
simultaneously, retaining sample integrity and delivering
consistent, accurate results.
The development of increasingly sophisticated biopharmaceutical
therapies requires the ability to measure and monitor critical
quality attributes in short timelines. The BioPhase 8800 system
enables high throughput, sensitive CE-SDS and CIEF analysis,
resulting in uncompromised accuracy for large sample sets. With
this system, scientists can quickly understand molecular
liabilities and ensure the development and manufacture of robust,
“Customers told us about their challenges transitioning to more
innovative biologics where samples are getting numerous and more
complex, and results are needed quicker. They are under pressure to
close the developability gaps earlier in the development process
and need faster analysis with confident results,” says Mani
Krishnan, Vice President of CE & Biopharma. “Today, we are
thrilled to usher in a new phase of biologic drug analysis with the
BioPhase 8800 system as we continue our collaborations with
biologics manufacturers at the forefront of innovation.”
Key features of the BioPhase 8800 system include:
- Parallel processing of eight samples dramatically
accelerates analysis and shortens new therapy development;
experiment design speed can increase from 1 month to as quick as 1
- High throughput, precise quantitation of critical quality
attributes for large sample sets delivers consistent,
comparable data throughout the pipeline, from bioprocessing to
R&D to QA/QC.
- Integrated detection modules to switch between UV and UV-LIF
detection makes it easy to go from one assay to the next
without sacrificing performance.
- Intuitive software interface and panel screen
featuring a simple, drag and drop method and sequence creation
complements innovative data analysis to accelerate characterization
from start to finish.
- Core biopharma applications through validated kits
simplify operations and minimizes user error.
“We have a history of innovation to address customer needs –
from the development of the industry first CE instrument, the P/ACE
2000, to the gold standard for CE-SDS analysis, the PA 800 system,”
says Joe Fox, President at SCIEX. “Now, virtually every biologic
drug in the market, and those undergoing clinical trials today use
our PA 800 system for purity analysis. Innovated from the ground up
to address the next generation of challenges, the BioPhase 8800
system is the next stage of this journey and we are excited to
embark on it with our customers.”
To learn more about the BioPhase 8800 system, visit here.
SCIEX delivers solutions for the precision detection and
quantification of molecules, empowering our customers to protect
and advance the wellness and safety of all. We have led the field
of mass spectrometry for 50 years. From the launch of the first
ever commercially successful triple quadrupole in 1981, we have
developed groundbreaking technologies and solutions that influence
life-changing research and outcomes.
Today, as part of the Danaher (NYSE: DHR) family of global
science and technology innovators, we continue to pioneer robust
solutions in mass spectrometry and capillary electrophoresis. Our
customers are able to quickly respond to environmental hazards,
better understand biomarkers relevant to disease, improve patient
care in the clinic, bring relevant drugs to market faster and keep
food healthier and safer.
That’s why thousands of life science experts around the world
choose SCIEX to get the answers they can trust to better inform
critical decisions that positively impact lives.
For more information, visit sciex.com.
Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.
Advances in human wellness depend on the power of precise
The SCIEX clinical diagnostic portfolio is For In Vitro
Diagnostic Use. Rx Only. Product(s) not available in all countries.
For information on availability, please contact your local sales
representative or refer to www.sciex.com/diagnostics. All other
products are For Research Use Only. Not for use in Diagnostic
Trademarks and/or registered trademarks mentioned herein,
including associated logos, are the property of AB Sciex Pte. Ltd.
or their respective owners in the United States and/or certain
other countries (see www.sciex.com/trademarks).
© 2021 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-13756-A.
version on businesswire.com: https://www.businesswire.com/news/home/20210901005696/en/
Lulu VanZandt Manager, Brand, Public Relations and Social Media,
SCIEX firstname.lastname@example.org +1 (508) 383-7163 M: +1 (508)
Historical Stock Chart
From Nov 2021 to Dec 2021
Historical Stock Chart
From Dec 2020 to Dec 2021